Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection

Serrano, Laura ; Algarate, Sonia (Universidad de Zaragoza) ; Herrero-Cortina, Beatriz ; Bueno, Jessica ; González-Barriga, Maria T. ; Ducons, Maria ; Montero-Marco, Jesica ; Acha, Beatriz ; Taboada, Ana ; Sanz-Burillo, Pilar ; Yuste, Cristina ; Benito, Rafael (Universidad de Zaragoza) ; RIPOVAC, Study Group

Resumen: Aims: Presence of anti-S1 region of SARS-CoV-2 spike protein was analysed, at two and eight months, in 477 immunocompetent healthcare workers in Zaragoza, Spain, vaccinated with mRNA-1273 (Moderna) or BNT162b2 (Pfizer). Methods and results: Antibody analysis was performed with Alinity i System (Abbott). At 2 months, 100% of vaccinated had anti-S1 IgG (mean = 13, 285 AU ml-1). This value was significantly higher with Moderna (18, 192 AU ml-1) than with Pfizer (10, 441 AU ml-1). The mean value of anti-S1 IgG after vaccination was significantly higher in patients with than without previous infection (18, 539 vs. 7919 AU ml-1); in both groups was significantly higher with Moderna than with Pfizer (21, 881 vs. 15, 733 AU ml-1 and 11, 949 vs. 6387 AU ml-1), respectively. At 8 months, 100% of patients were IgG positive, with higher levels with Moderna than with Pfizer. Nevertheless, in ensemble of cases, a mean decrease of antibody levels of 11, 025 AU ml-1 was observed. Conclusion: At 2 and 8 months after vaccination, IgG response persists with both vaccines but with important decrease which suggests the need for revaccination. Significance and impact of study: The study contributes to know the immune status after vaccination with two of more used anti-SARS-CoV-2 vaccines. This knowledge is important for establishing the best vaccination strategy. © 2022 The Authors. Journal of Applied Microbiology published by John Wiley & Sons Ltd on behalf of Society for Applied Microbiology.

Idioma: Inglés

DOI: 10.1111/jam.15699

Año: 2022

Publicado en: Journal of Applied Microbiology 133, 3 (2022), 1969-1974
ISSN: 1364-5072

Factor impacto JCR: 4.0 (2022)

Categ. JCR: MICROBIOLOGY rank: 58 / 135 = 0.43 (2022) - Q2 - T2
Categ. JCR: BIOTECHNOLOGY & APPLIED MICROBIOLOGY rank: 55 / 158 = 0.348 (2022) - Q2 - T2

Factor impacto CITESCORE: 6.7 - Biochemistry, Genetics and Molecular Biology (Q2) - Immunology and Microbiology (Q2) - Medicine (Q1)

Factor impacto SCIMAGO: 0.774 - Applied Microbiology and Biotechnology (Q2) - Medicine (miscellaneous) (Q2) - Biotechnology (Q2)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)